The efficacy of topical Hydroquinon with and without using Erbium YAG LASER in treatment of melasma

Comparison of efficacy and safety of topical Hydroquinon with and without using fractional Erbium YAG LASER in treatment of melasma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181201041812N1

Enrollment

Registered

2019-09-25

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: Topical Hydroquinon4% as kligman formula, every night with fractional Erbium YAG LASER. Intervention 2: Control group: Hydroquinon cream 4% as kligman formula night

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Symmetrical melasma in both half of the face Patients satisfaction Skin type 1-3

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Use of alpha hydroxy acids and other drugs effect on pigmentation during past 4 weeks Use of topical and oral retinoid Use of topical steroid Use of Oral Contraceptive Pills Chemical peeling ,microderm abrasion, derm abrasion or LASER during past 3 months History of keloid History of past sensitivity to hydroquinon History of thyroid dysfunction LASER therapy in past 3 months

Design outcomes

Primary

Measure	Time frame
Pigmentation. Timepoint: Before intervention,at the end of intervention,1 mouth and 3 mouths after end of intervention. Method of measurement: Modified Melasma Area and Severity Index(mMASI) score,digital photography,patient satisfaction(questionnaire),physician assessment.;Topical adverse effects. Timepoint: Every month in intervention period and the end of intervention. Method of measurement: Questionnaire and observation.	—

Measure

Time frame

Pigmentation. Timepoint: Before intervention,at the end of intervention,1 mouth and 3 mouths after end of intervention. Method of measurement: Modified Melasma Area and Severity Index(mMASI) score,digital photography,patient satisfaction(questionnaire),physician assessment.;Topical adverse effects. Timepoint: Every month in intervention period and the end of intervention. Method of measurement: Questionnaire and observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Nasiri

Tehran University of Medical Sciences

drfatemehnasiri@yahoo.com+98 21 5563 3949

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026